期刊
BLOOD
卷 119, 期 9, 页码 2100-2105出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2011-11-390658
关键词
-
类别
资金
- Mayo Clinic
- National Institutes of Health [CA96028, P01 CA62242]
- Predolin Foundation
- Mayo Clinic Cancer Center
- Mayo Foundation
- Medtronic
- Otsuka
- Celgene
- Genzyme
- BMS
- AMGEN
- Cylene
- Onyx
- Millennium
- Novartis
Routine incorporation of FISH into multiple myeloma (MM) diagnostic testing has led to a better appreciation of the heterogeneity of genetic abnormalities associated with this disease. We studied a group of 484 patients with newly diagnosed symptomatic MM to better understand the prevalence of the various abnormalities and the prognostic significance of the overlapping abnormalities. A translocation involving the IgH locus and 1 of the 5 recurrent partner chromosomes was seen in 161 (33%) patients, and 275 (57%) had trisomy of at least 1 odd-numbered chromosome. High-risk FISH, defined as the presence of t(4;14), t(14;16), t(14;20), or loss of P53, was seen in 115 (24%) patients; the median overall survival for this group was 3.9 years, compared with not reached for standard-risk patients (P < .001). Among the patients with high-risk FISH, 49 patients who also had at least 1 trisomy had a median overall survival that was not reached, compared with 3 years for high-risk patients without a concurrent trisomy (P = .01). Based on the current findings, we conclude that the presence of trisomies in patients with t(4;14), t(14;16), t(14;20), or p53 deletion abnormalities in MM ameliorates the usual adverse impact associated with these prognostic markers. (Blood. 2012; 119(9): 2100-2105)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据